Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ticarcillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.62 |
| ▸ | RECQL | P46063 | 4/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | TEK | Q02763 | 1/20 | 0.62 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | RARB | P10826 | 1/20 | 0.60 |
| ▸ | RARG | P13631 | 1/20 | 0.60 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.60 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.60 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ticarcillin SCHEMBL10738085 | 1.00 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL10738099 | 1.00 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL5047437 | 1.00 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL28757995 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL9929365 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL193733 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL4935398 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL4228859 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL4935408 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL27742456 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 29884 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637481-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2026-05-26 | — | — | US | claimed |
| WO-2026104587-A1 | CYCLIC BORONIC ACID ESTERS USEFUL AS ADJUVANTS IN THE TREATMENT OF BACTERIAL INFECTIONS | ADJUTEC PHARMA AS (NO) | 2026-05-21 | — | — | WO | claimed |
| EP-4743580-A1 | EFFICIENT TRANSGENE-FREE GENOME EDITING IN PLANTS IN THE T0 GENERATION BASED ON A CO-EDITING STRATEGY | University of Florida Research Foundation, Incorporated (US) | 2026-05-20 | — | — | EP | claimed |
| CN-115215923-B | Macrocyclic broad-spectrum antibiotics | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | claimed |
| EP-4739326-A2 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR Biome ApS (DK) | 2026-05-13 | — | — | EP | claimed |
| US-20260115234-A1 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR BIOME APS (DK) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260091089-A1 | Pyocyanine Demethylases and related Phenazine Degrading Agents Compositions, Methods and Systems for Interfering with Viability of Bacteria | CALIFORNIA INST OF TECHN (US) | 2026-04-02 | — | — | US | claimed |
| US-12590108-B2 | Boracic acid compound | PHAENO THERAPEUTICS CO., LTD (CN) | 2026-03-31 | — | — | US | claimed |
| EP-4712972-A1 | COMBINATION THERAPY FOR BACTERIAL INFECTIONS COMPRISING ZINC-CHELATOR, BETA-LACTAM ANTIBIOTIC AND SERINE BETA-LACTAMASE INHIBITOR | Adjutec Pharma AS (NO) | 2026-03-25 | — | — | EP | claimed |
| EP-0026409-A1 | Combinations of active ingredients, pharmaceutical preparations, as well as their preparation | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-04-08 | — | — | EP | claimed |
| EP-0003618-B1 | ANTIBACTERIAL COMPOSITION AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-01-28 | — | — | EP | claimed |
| US-4210635-A | A PHOSPHONIC ACID DERIVATIVE AND AN ANTIBIOTIC | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-07-01 | — | — | US | claimed |
| EP-0007717-A1 | Clavulanic acid derivatives, a process for their preparation, their use, and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1980-02-06 | — | — | EP | claimed |
| EP-0004925-A1 | Synergistic mixtures of antibiotics and process for their production | CIBA-GEIGY AG (CH) | 1979-10-31 | — | — | EP | claimed |
| EP-0005014-A1 | Clavulanic acid derivatives, preparation and compositions | BEECHAM GROUP PLC (GB) | 1979-10-31 | — | — | EP | claimed |
| EP-0003618-A1 | Antibacterial composition and use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1979-08-22 | — | — | EP | claimed |
| US-4143134-A | BACTERICIDES, ANTIBIOTIC POTENTIATORS | HOFFMANN-LA ROCHE INC. (US) | 1979-03-06 | — | — | US | claimed |
| US-4134972-A | OLIGOPEPTIDES | HOFFMANN-LA ROCHE INC. (US) | 1979-01-16 | — | — | US | claimed |
| US-4127649-A | PEPTIDES | HOFFMANN-LA ROCHE INC. (US) | 1978-11-28 | — | — | US | claimed |